Search
for
Sort by
Research 151–180 of 166
- Drug-induced scarring and permanent alopecia
- Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
- Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
- A guide to diagnosis and management of hypertrichosis
- Botryococcus terribilis Ethanol Extract Exerts Anti-inflammatory Effects on Murine RAW264 Cells
- Perspective Chapter: Appraisal of Paclitaxel (Taxol) Pros and Cons in the Management of Cancer – Prospects in Drug Repurposing
- Treatment of Chemotherapy Induced Alopecia
- Research Progress on Construction Technology of 3D Human Skin Models and Its Application Prospects in Dermatology
- Exploring the mechanism of Platycladi Cacumen in intervening androgenetic alopecia based on network pharmacology, molecular docking, and molecular dynamics simulation
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Drug-Loaded Extracellular Vesicle-Based Drug Delivery: Advances, Loading Strategies, Therapeutic Applications, and Clinical Challenges
- Cancer-Related Alopecia Risk and Treatment
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- Effectiveness and Safety Profile of Cisplatin Versus Nab-Paclitaxel Concomitant Chemoradiotherapy in Postoperative Early-Stage Cancer of Cervix
- A linear and reticulate crusted keratotic papulopustular eruption: a rare presentation of PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) complex
- The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth? - eScholarship
- Trichomegaly of the eyelashes following treatment with cetuximab
- Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation
- Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
- Cetuximab-Associated Elongation of the Eyelashes
- Incidence and management of cutaneous toxicities associated with cetuximab
- Cetuximab-induced hypertrichosis of the scalp and eyelashes
- Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
- Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment
- Cetuximab Induced Hidrocystomas: A Case Report
- Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab
- BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- Perifollicular Xanthomas Associated with Epidermal Growth Factor Receptor Inhibitor Therapy
- Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients